Prognostic Factors and Recurrence of Small Hepatocellular Carcinoma after Hepatic Resection or Microwave Ablation: A Retrospective Study

Wang, Zhi Li; Liang, Ping; Dong, Bao Wei; Yu, Xiao; Yu, De Jiang

doi:10.1007/s11605-007-0310-0

Cited by 91 publications

(82 citation statements)

References 31 publications

(24 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Many studies have reported on the association between alterations in MET and poor prognosis and/or disease severity in human cancers (25)(26)(27)(28). These findings support the hypothesis that specific alterations in MET may provide predictive capacity for identifying patients most likely to benefit from MET inhibitor therapy.…”

Section: Discussionsupporting

confidence: 56%

“…In addition, the HGF/MET signaling pathway has been shown to be activated during the genesis and progression of hepatocellular carcinoma. Many reports have highlighted the prevalence of MET gene and protein expression in hepatocellular carcinoma, and have investigated the role of MET signaling in hepatocellular carcinoma progression and maintenance (24)(25)(26)(27)(28). The importance of MET signaling in these processes suggests that the status of MET gene amplification and/or protein expression in patients with hepatocellular carcinoma may serve as potential biomarkers for prognosis or response to anti-HGF/MET therapy.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Preclinical Evaluation of AMG 337, a Highly Selective Small Molecule MET Inhibitor, in Hepatocellular Carcinoma

Du¹,

Caenepeel

Shen³

et al. 2016

Molecular Cancer Therapeutics

View full text Add to dashboard Cite

Aberrant hepatocyte growth factor (HGF)/MET signaling has been implicated in hepatocarcinogenesis, suggesting that MET may serve as an attractive therapeutic target in hepatocellular carcinoma. We sought to investigate the in vitro and in vivo antitumor activity of AMG 337, a potent and highly selective small molecule MET kinase inhibitor, in preclinical models of hepatocellular carcinoma. The antiproliferative activity of AMG 337 was evaluated across a panel of hepatocellular carcinoma cell lines in a viability assay. Daily oral administration was used to evaluate the in vivo antitumor activity of AMG 337 in two patientderived xenograft (PDX) models of hepatocellular carcinoma (LI0612 and LI1078). AMG 337 exerted potent antiproliferative activity against 2 of 40 hepatocellular carcinoma cell lines, namely, MHCC97H (IC 50 , 0.015 mmol/L) and HCCLM3 (IC 50 , 0.025 mmol/L). Both sensitive cell lines showed MET amplification (MET/CEN-7 >2.0) assessed by FISH, and high MET expression (3þ IHC) assessed by IHC. AMG 337 potently inhibited p-MET in all cell lines with detectable levels of total MET. However, the dose-dependent inhibition of downstream effectors of HGF/MET signaling, including p-GAB1, p-AKT, and p-ERK, was limited to those cell lines sensitive to AMG 337 in a viability assay (MHCC97H and HCCLM3). AMG 337 significantly inhibited tumor growth at all doses tested in the MET-amplified and MET-high-expressing hepatocellular carcinoma PDX model LI0612 and had no effect on tumor growth in the non-METamplified and MET-low-expressing hepatocellular carcinoma PDX model LI1078. AMG 337 represents a promising and novel therapeutic strategy for targeting hepatocellular carcinomas with a dependence on HGF/MET signaling.

show abstract

Section: Discussionsupporting

confidence: 56%

Section: Discussionmentioning

confidence: 99%

Preclinical Evaluation of AMG 337, a Highly Selective Small Molecule MET Inhibitor, in Hepatocellular Carcinoma

Du¹,

Caenepeel

Shen³

et al. 2016

Molecular Cancer Therapeutics

View full text Add to dashboard Cite

show abstract

“…42 Moreover, other studies have shown that expression of VEGF in HCC was correlated with the probability of recurrence after tumor resection or ablation. [43][44][45][46] Collectively, these findings suggest that tissue VEGF expression in HCC may indicate more advanced disease and reduced median survival. However, these studies had relatively small patient numbers and used different VEGF detection assays.…”

Section: Molecular Interactions With Vegfmentioning

confidence: 92%

Vascular endothelial growth factor in the management of hepatocellular carcinoma

Kaseb

Hanbali

Cotant

et al. 2009

Cancer

109

View full text Add to dashboard Cite

The consumption of antidepressants, especially selective serotonine reuptake inhibitors (SSRI) has been increasing. Because a large fraction of the population is exposed, even a small excess of risk with respect to cancer should be considered. We carried out a record linkage study in Finland utilizing nationwide databases of reimbursed medication and cancer. The study population included all antidepressant drug (AD) users in Finland who had purchased at least 1 prescription between 1998 and 2005, and who had no cancer diagnosis at the date of first purchase. A control population without AD usage (matched by age and sex) was also included. Data consisted of 418,588 pairs of individuals that cumulated 3.3 million person‐years with an average of 4.0 years of follow‐up. 19,365 cancer cases were observed. The most frequent cancers were breast, prostate, lung, colon, and brain cancer. In general, only few associations between the utilization of AD and cancer could be detected. Over four years exposure to AD showed a weak association with increased colon and breast cancer incidence, which could have been caused by bias. As conclusion, no clear evidence of neither beneficial nor harmful association between usage of antidepressant and cancer was found.

show abstract

“…[4][5][6] However, the long-term survival of patients with HCC remains unsatisfactory because of the high incidence of recurrence and metastasis after hepatic resection, with a 5-year survival rate of 20% to 30% reported in the literature. 7,8 To predict recurrence, metastasis, and prognosis in patients with HCC after hepatic resection is a significant clinical issue. Although the identification of many prognostic markers of HCC, such as vascular endothelial growth factor, osteopontin, and transforming growth factor-b, resulted from extensive clinical as well as basic research efforts, the available markers still are not able to accurately predict the survival of patients with HCC.…”

mentioning

confidence: 99%

p53‐induced RING‐H2 protein, a novel marker for poor survival in hepatocellular carcinoma after hepatic resection

Wang

Yang

Guo

et al. 2009

Cancer

View full text Add to dashboard Cite

Novel copolyacrylates containing various molar ratios of 5,10,15‐tri[p‐(9‐methoxy‐triethylenoxy)phenyl]‐20‐(p‐acryloxyphenyl)porphyrin units in the chains have been synthesized, and their chemical structure was determined by NMR and MALDI‐TOF mass spectrometry. Sensing response of the synthesized copolymers has been tested for trifluoroacetic and hydrochloric acids and nitrogen dioxide analytes. The reported sensing data indicate that porphyrin units are interacting with analytes in a reversible fashion. © 2010 Wiley Periodicals, Inc. J Polym Sci Part A: Polym Chem, 2011

show abstract

Prognostic Factors and Recurrence of Small Hepatocellular Carcinoma after Hepatic Resection or Microwave Ablation: A Retrospective Study

Cited by 91 publications

References 31 publications

Preclinical Evaluation of AMG 337, a Highly Selective Small Molecule MET Inhibitor, in Hepatocellular Carcinoma

Preclinical Evaluation of AMG 337, a Highly Selective Small Molecule MET Inhibitor, in Hepatocellular Carcinoma

Vascular endothelial growth factor in the management of hepatocellular carcinoma

p53‐induced RING‐H2 protein, a novel marker for poor survival in hepatocellular carcinoma after hepatic resection

Contact Info

Product

Resources

About